Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past 2019 predictions along with my grades for them here. I gave myself a B+ for […]
20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020 Read More »
Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do?
B+ on my report card on my 20 stem cell predictions for 2019 Read More »
Masayo Takahashi is a leading stem cell researcher doing translational and clinical research on vision. She’s doing pioneering work on using pluripotent stem cells as a basis for helping patients with vision loss such as due to macular degeneration. She won The Niche’s Stem Cell Person of the Year Award in 2014 and a number
Masayo Takahashi (高橋 政代): exciting vision work advancing including with photoreceptors Read More »
Today’s post is a review of Unnatural Selection, the new Netflix science docuseries focused on CRISPR and other disruptive genetic and reproductive technologies. The show is an interesting mix of personalities and stories from patients, scientists, biohackers, and more. One patient thread is the story of a wonderful little boy named Jackson Kennedy. He wants
Unnatural Selection review: captivating mind-bender but needed more science Read More »
US Stem Cell, Inc. reports in a new SEC filing that its key leader Kristin Comella has resigned as of September 1. I never thought I’d see the day when Kristin Comella and US Stem Cell, Inc. parted ways. To me Comella seemed like the driving force behind the company, which is now subject to
Kristin Comella resigns from embattled clinic firm US Stem Cell Read More »
I’m a biologist and genetics researcher, but as I have time I still squeeze in a little research on stem cell clinics when I can, and my new pub in Regenerative Medicine is notable for looking at changes in clinic firms in a unique kind of way. In the paper I went back to the
My Regenerative medicine pub tracking 100s of stem cell clinics over 3 years Read More »
It can be kind of a big deal when politicians, especially at the federal level, write the FDA about stem cells. Is this going to be good news or bad? Some combination? I tend to worry that some senators or representatives might pressure the FDA to weaken oversight. However, lately it seems like the opposite
Congress pushes FDA on stem cell clinic mess in new letter Read More »
In the latest blow to the unproven stem cell clinic industry, a California federal district court judge just granted class status to a lawsuit against the fat stem cell clinic Stemgenex. (update: Stemgenex has since filed for bankruptcy). What this means in practical terms is that the lawsuit alleging fraud in marketing by the clinic
Today the United States District Court of the Southern District of Florida entered a permanent injunction against stem cell clinic firm US Stem Cell and co-defendants including U.S. Stem Cell Clinic. Patients have been harmed by the unproven treatments sold by these firms. US Stem had lost the case a couple weeks back, but now
Permanent injunction on clinic firm US Stem Cell is big blow to fat clinics Read More »
It’s been a big week already for the stem cell field due to the court ruling against US Stem Cell Inc. and that the FDA can define stromal vascular fraction (SVF) as a drug (see my old rough sketch of how SVF is sometimes manufactured; my impression is that the company does this slightly differently).
Reactions to historic stem cell clinic court loss, new court order, & what happens next? Read More »